Alessandra Boccaccino

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti et al. · British Journal of Cancer · 2020 · 354 citations · Full text

Medicine, Immunology, Oncology +17

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini et al. · BMC Cancer · 2020 · 84 citations · Full text

Medicine, Immunology, Oncology +17

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Daniele Rossini, Carlotta Antoniotti, Sara Lonardi et al. · Journal of Clinical Oncology · 2022 · 78 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Marta Schirripa, Floriana Nappo, Chiara Cremolini et al. · Clinical Colorectal Cancer · 2020 · 69 citations

Medicine, Cancer Biology, Oncology +16